- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer
© Kahlert et al; licensee BioMed Central Ltd. 2011
Received: 25 November 2010
Accepted: 27 June 2011
Published: 27 June 2011
Aldehyde deyhdrogenase 1 (ALDH1) has been characterised as a cancer stem cell marker in different types of tumours. Additionally, it plays a pivotal role in gene regulation and endows tumour cells with augmented chemoresistance. Recently, ALDH1A1 has been described as a prognostic marker in a pancreatic cancer tissue microarray. The aim of this study was to reevaluate the expression of ALDH1A1 as a prognostic marker on whole-mount tissue sections.
Real-time-quantitative-PCR (qRT-PCR) and Western blotting were used to evaluate the expression profile of ALDH1A1 in seven pancreatic cancer cell lines and one non-malignant pancreatic cell line. Immunostaining against ALDH1A1 and Ki-67 was performed on paraffin-embedded samples from 97 patients with pancreatic cancer. The immunohistochemical results were correlated to histopathological and clinical data.
qRT-PCR and Western blotting revealed a different expression pattern of ALDH1A1 in different malignant and non-malignant pancreatic cell lines. Immunohistochemical analysis demonstrated that ALDH1A1 was confined to the cellular cytoplasm and occurred in 72 cases (74%), whereas it was negative in 25 cases (26%). High expression of ALDH1A1 was significantly correlated to an increased proliferation rate (Spearman correlation, p = 0.01). Univariate and multivariate analyses showed that decreased expression of ALDH1A1 is an independent adverse prognostic factor for overall survival.
Immunonhistochemical analysis on whole-mount tissue slides revealed that ALDH1A1 is more abundantly expressed in pancreatic cancer than initially reported by a tissue microarray analysis. Moreover, high expression of ALDH1A1 correlated significantly with the proliferation of tumour cells. Intriguingly, this study is the first which identifies low expression of ALDH1A1 as an independent adverse prognostic marker for overall survival in pancreatic cancer.
Although the incidence of pancreatic cancer amounts only to 3% of all tumours, it is a major cause of cancer-related death in Western countries . Surgical resection remains the only potentially curative therapeutic option. At the time of initial diagnosis, only a minority of patients with pancreatic cancer are still in a curable resectable stage . Even if a potentially curative resection can be performed, the five-year overall survival is low at 10-25% [2–4].
Current prognostic markers for curatively resected pancreatic cancer include lymph node status, tumour type and histological grade [2, 4, 5]. However, these prognostic markers only poorly predict metastatic progression or tumour response to medical treatment in the individual patient. Therefore new biomarkers are required in order to stratify patients into different risk categories, thus allowing a more specific treatment regimen.
Stem cell markers are a promising group of new biomarkers. In pancreatic cancer, several surface markers have been identified to provide a subpopulation of the tumour cells with so-called stem cell characteristics. These cancer stem cell markers include CD44 , CD24 and CD133 . Their relevance as strong prognostic markers in pancreatic cancer has already been evaluated [8, 9].
In this study, we have focused on aldehyde dehydrogenase 1A1 (ALDH1A1), which has been recently identified to label tumour stem cells in breast cancer , colon cancer  lung cancer  and head and neck squamous cancer . ALDH1 belongs to the superfamily of NAD(P)(+)-dependent enzymes which metabolise a wide spectrum of endogenous and exogenous aliphatic and aromatic aldehydes . It is distributed ubiquititously in many human tissues where it is localised in the cellular cytoplasm. By the formation of retinoic acid it acts as a pivotal modulator for gene regulation and cell differentiation . Moreover, ALDH1 has a strong activity for detoxifying aldophosphamide, hence providing overexpressing cells with chemoresistance against cyclophosphamide .
Besides to gynaecological tumours and tumours of the respiratory tract [10, 12, 16], increased expression of ALDH1A1 in a pancreatic cancer tissue microarray has been recently described to correlate with a dismal prognosis . On the contrary, increased expression of ALDH1 in ovarian cancer correlates with more favourable disease-free and overall survival . Conversely, overexpression of ALDH1 in colorectal cancer is not related to differences in survival at all . However, most of these results are based on tissue microarrays. This method is a very sophisticated tool to screen a large number of clinical specimens, but it might obscure essential findings by evaluating only small punched random samples from morphologically representative tissue areas. Hence, the aim of our study was to reevaluate the expression pattern of ALDH1A1 in pancreatic cancer on whole-mount tissue slides and to correlate these results with clinical and pathological data. Furthermore, ALDH1-positive non-pancreatic tumour cells have been found to have a high Ki-67 expression [12, 20, 21]. Therefore, we focused on the correlation between the expression of ALDH1A1 and the proliferation rate of tumour cells in pancreatic cancer samples. Our study demonstrates that high expression of ALDH1A1 is significantly correlated with the proliferation rate of pancreatic tumour cells. Intriguingly, this study is the first which identifies low expression of ALDH1A1 as an independent adverse prognostic marker for overall survival in pancreatic cancer.
Correlation between expression of ALDH1A1 in pancreatic cancer and clinical and pathological parameters
Number of cases
< mean 65 years
≥ mean 65 years
Lymph node status
AJCC tumour stage
Immunohistochemical staining for ALDH1A1 was performed as previously described . Briefly, 1-2 μm sections of formalin-fixed, paraffin-embedded tumour samples were mounted on object slides (SUPERFROST® PLUS microscope slides, Menzel, Braunschweig, Germany) and incubated at 37°C overnight. After de-waxing in xylene and ethanol, antigen retrieval was achieved by boiling in a microwave oven for 5 min (pH 6.0, 0.94 ml Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA)/100 ml distilled water) three times. After immersing slides in a 3.0% hydrogen peroxidase solution in methanol for 20 min in order to inhibit endogenous peroxidase activity, non-specific binding sites were blocked by pre-incubation with 10% normal goat serum (Vector Laboratories) in 1 mol/L PBS for 30 min at room temperature. Primary antibodies against ALDH1A1 (mouse IgG1, clone 44, BD Transduction Laboratories™, Europe, dilution 1:200, rabbit IgG, clone EP1933Y, Novus Biologicals, USA, 1:200, Rabbit polyclonal, Novus Biologicals, USA 1:50) and the IgG - negative control (mouse IgG, BD Pharmingen, Europe, 1:100) were incubated at 4°C overnight. Slides were loaded with secondary antibody coupled to peroxidase-conjugated polymers (EnVision®+ System, DakoCytomation A/S, Denmark) for 30 minutes. Afterwards, the immunoreaction was visualised by using AEC Substrate Chromogen (DakoCytomation A/S) according to the instructions of the manufacturer. Eventually, sections were counterstained with haematoxylin, dehydrated in graded concentrations of ethanol and mounted.
Staining against Ki-67 was performed at the tissue bank of the National Centre for Tumour Disease (NCT) Heidelberg by means of an automated immunostainer (Dako Autostainer A/S, Denmark) according to the manufacturer's instructions. Briefly, paraffin was removed with xylene and ethanol before the sections were de-masked for 15 min (pH 6.0, 0.94 ml Antigen Unmasking Solution, (Vector Laboratories)/100 ml distilled water). The slides were loaded with the primary antibody (Ki-67, Dako, A/S Denmark 1:200) and with the secondary antibody (Dako REAL Biotinylated Secondary Antibodies A/S Denmark) for 30 minutes, respectively. As the detection system, a streptavidin-peroxidase complex (Dako REAL Detection System) was used and the reactions were visualised by using Dako REAL AEC/H2O2 Substrate Solution (CHROM). Finally, the slides were counterstained with haematoxylin.
Evaluation of immunohistochemistry was performed by scanning the whole section at medium (50×) and high magnification (200×). Staining intensity and the percentage of positive tumour cells in the whole section were estimated by three independent researchers (CK, JB, NM) and two pathologists (CM, FB) on a blind basis. A multi-head microscope was used and consensus was reached for each slide. The staining intensity was classified as absent: 0, weak: 1, medium: 2 and strong: 3. The percentage of positive cells was categorised as 0: (< 5%), 1 (5-25%), 2 (> 25%-50%), 3 (> 50%-75%), and 4 (> 75%). By multiplying the value of the staining intensity with the categorised value of positive cells, a final immunohistochemical score was obtained. This scoring system has been suggested as a tool to evaluate prognostic biomarkers with broadly different levels of expression and intensity . The proliferation rate of each tumour specimen was determined on a blind basis by categorising the estimated number of tumour cells stained positive against Ki-67 as 0: (< 5%), 1 (5-15%), 2 (> 15%-25%), 3 (> 25%).
The following cell lines were used: SU8686, BxPC3, PANC-1, AsPC-1, MiaPaCa-2, ACBRI (all purchased from the American Type Culture Collection (ATCC), Manassas, VA 20108, USA), Colo357 (provided by T. Welsch) as well as T3M-4 (Cell Bank, RIKEN BioResource Centre, Japan). In June 2010, the cell lines were re-tested and re-authenticated by analysing cell samples for eight polymorphic short random repeat (STR) loci (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, Germany).
Tumour cell lines were maintained in RPMI-1640 (Sigma, St. Louis, MO), supplemented with 10% (v/v) foetal calve serum (FCS), 100 U/ml penicillin and 100 μg/ml streptomycin. ACBRI cells were maintained in CSC Certified Complete Medium (CellSystems). All cells were cultured in a humidified atmosphere of 5% CO2 at 37°C.
Total RNA isolation and real-time qPCR
Total RNA from the cell lines was extracted employing the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the instruction manual. One microgram of total RNA was reverse transcribed using the miScript Reverse Transcription Kit (Qiagen). Ten nanograms of the resulting cDNA were used for quantification by qPCR (SYBR Green PCR Kit, Qiagen) in a Roche Light Cycler™ (Roche Diagnostics GmbH, Mannheim, Germany). Ready primer pairs specific for ALDH1A1 and 18S were purchased from Qiagen (Hs_ALDH1A1_1_SG QuantiTect Primer Assay, Cat. No. QT00013286 and Hs_RRN18S_1_SG QuantiTect Primer Assay, Cat. No. QT00199367). After an initial incubation at 95°C for 10 minutes, 40 cycles were carried out (15 sec at 95°C, 15 sec at 60°C, 30 sec at 72°C). All experiments were performed as triplicates. ALDH1A1 expression was normalised to 18 s and quantified as previously described .
Cells were separated with 2 ml Accutase (PAA Cell Culture Company), washed with PBS and lysed in a cell lysis buffer (RIPA) with a protease inhibitor (Complete Mini, Roche Applied Science, Mannheim, Germany). Subsequently, they were disrupted by sonication and the protein concentration of the supernatant (centrifugation: 10 min, 11000 rpm, 4°C) was determined by a BCA kit (Thermo Scientific, Schwerte, Germany). Thirty micrograms of protein were separated on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane (BioRad, Munich, Germany) and incubated with antibodies against ALDH1A1 (Mouse IgG1, clone 44, BD Transduction Laboratories™) and α/ß-Tubulin (Cell Signaling Technology, Danvers, MA 01923, USA) with a dilution of 1:500. The horseradish peroxidase-conjugated secondary antibody anti-rabbit or anti-mouse (Sigma-Aldrich, Munich, Germany) was added at a dilution of 1:1000 after repeated washing with a wash/blocking buffer (PBS, Tween20 0.1% (v/v), skim milk powder 7,5% (w/v)). The antigen-antibody complexes were detected by using an ECL kit (Thermo scientific, Schwerte, Germany) according to the manufacturer's recommendations. All experiments were performed as triplicates.
The software package SPSS, version 11.0 (SPSS, Chicago, IL, USA) was used for all calculations. The Chi-square (χ2) test was applied to examine the correlation between ALDH1A1 expression and clinical and pathological parameters. The Spearman correlation was employed for determining a correlation between the expression of ALDH1A1 and Ki-67. The Kaplan-Meier method was used to visualise overall and recurrence free survival curves, and differences between survival curves were assessed with the log-rank test for univariate analysis.
The Cox proportional hazards regression model was conducted on all covariates that showed a significant association with overall survival in the univariate analysis. The P-values of all statistical tests were two-sided and P < 0.05 was considered significant.
Evaluation of specificity of ALDH1A1 immunohistochemistry
To validate the specificity of immunohistochemical staining against ALDH1A1, we repeated immunohistochemistry in 10 representative specimens with three different antibodies against ALDH1A1 and one IgG negative control. When comparing the immunohistochemical results of the three antibodies in sequential sections, they displayed similar cytoplasmic expression patterns in pancreatic cancer and in non-malignant cells, though the staining intensity of the polyclonal antibody was weaker than the staining intensity of the monoclonal antibodies (data not shown). These results, in addition to the Western blot analysis, confirmed the specificity of the anti-ALDH1A1 staining. For immunohistochemical evaluation of all clinical specimens, we used only the mouse monoclonal antibody (mouse IgG1, clone 44, BD Transduction Laboratories™, Europe), which had been previously used successfully [10, 12, 18, 20].
Expression of ALDH1A1 in pancreatic cell lines
Expression of ALDH1A1 and Ki-67 in normal pancreatic tissue and pancreatic cancer cells
In non-malignant pancreatic tissue, adjacent to pancreatic cancer in 60 cases, we observed strong cytoplasmic expression of ALDH1A1 in the pancreatic islet cells, in the acinar epithelium and in the ductal epithelial cells. The staining intensity displayed a homogenous pattern: islet cells usually revealed a strong staining intensity, while acinar and ductal epithelial cells revealed a moderate staining intensity.
The percentage of positive cells was categorised as follows: 0 (< 5%): 25 samples (26%), 1 (5-25%): 18 samples (18%), 2 (26-50%): 16 samples (17%), 3 (51-75%): 18 samples (18%), 4 (> 75%): 20 samples (21%). As already previously reported in a small cohort of patient samples , high expression of ALDH1A1 was more often observed in well-differentiated tumours, though the correlation between expression and tumour grades did not reach statistical significance (Table 1).
The distribution of ALDH1A1 expression according to the immunohistochemical score was: 0: 25 samples, 1: 8 samples, 2: 10 samples, 3: 5 samples, 4: 11 samples, 6: 11 samples, 8: 3 samples, 9: 8 samples and 12: 17 samples.
The percentage of Ki-67 positive cells was categorised as follows 0 (< 5%): 27 samples (28%), 1 (5-15%): 27 samples (28%), 2 (> 15%-25%): 23 samples (23%), 3 (> 25%): 20 samples (21%). There was no difference in staining intensity among all samples.
Relationship between the expression of ALDH1A1 and Ki-67
Recently, ALDH1 positive tumours have been found to have a high Ki-67 expression and to correlate positively with an increased proliferative capacity in vitro [12, 20, 21]. Therefore, we performed immunostaining against Ki-67 in consecutive sections and compared the percentage of Ki-67 positive cells with the immunohistochemical score of ALDH1A1 in pancreatic cancer (Figures 2E-H). The correlation between the proliferation rate and the immunohistochemical score of ALDH1A1 expression was shown to be significant (p = 0.01).
Low expression of ALDH1A1 is an independent prognostic marker in pancreatic cancer
To compare the expression of ALDH1A1 with clinical and pathological parameters, samples were grouped as ALDH1A1Low (immunohistochemical score ≤ median immunohistochemical score = 4) and as ALDH1A1High (immunohistochemical score > median immunohistochemical score = 4). The Chi-square test revealed no significant correlation between ALDH1A1 expression to age, gender, lymph node status, grading, American Joint Cancer Committee (AJCC) tumour stage, or resection status (Table 1).
Univariate analysis for prognostic parameters in pancreatic cancer for median overall survival (OAS) and median recurrence-free (RFS).
No. of Cases
No. Of cases
Lymph node status
AJCC tumour stage
Multivariate analysis (Cox regression model) of prognostic parameters for overall survival in pancreatic cancer
95% CI of Relative Risk
Expression negative/low vs. High
Adjuvant chemotherapy vs. no adjuvant chemotherapy
Subgroup analysis of ALDH1A1 expression in patients with adjuvant chemotherapy and no adjuvant treatment
Multivariate analysis (Cox regression model) of prognostic parameters for overall survival in pancreatic cancer in the subgroup of patients having received adjuvant chemotherapy
95% CI Relative Risk
expression low vs. high
In the smaller subgroup of patients having not received chemotherapy postoperatively with adjuvant intentions (n = 19), different expression of ALDH1A1 had no significant impact as a prognostic marker on overall survival (p = 0.74) by univariate analysis nor on recurrence-free survival (p = 0.35) by univariate analysis.
In our study, we have demonstrated that low expression of ALDH1A1 is an independent prognostic marker for shortened disease-free and overall survival in ductal adenocarcinoma of the pancreas. These results are very conflicting to a recent published study by Rasheed et al., who have described increased expression of ALDH1A1 in pancreatic cancer to correlate with a dismal prognosis . Since Rasheed et al. have evaluated the expression of ALDH1A1 by tissue microarrays, whereas we performed our immunohistochemical analysis on whole-mount tissue slides, methodological differences may explain these opposing results. However, by evaluating whole-mount tissue slides, we found ALDH1A1 to be expressed very heterogeneously within the tumour bulk. In fact, while Rasheed et al. claimed only 34% of the immunostained tumour samples as positive, we observed a much higher fraction of 74% of tumour specimen to be positive. Hence, using only 0.6 mm random tissue samples from morphologically representative tissue areas might obscure essential findings and result in an increased rate of false-negative results.
However, akin to the observations by Morimoto et al. in breast cancer  and by Jiang et al. in lung cancer cell lines , we have found a positive correlation between an increased expression of ALDH1A1 and a higher proliferation rate. Furthermore, we observed strong expression of ALDH1A1 more frequently in well-differentiated tumour samples. With these findings, it is tempting to hypothesise, as to why overexpression of ALDH1A1 correlates with a more favorable clinical outcome: assuming that conventional cytotoxic therapy aims mainly at the proliferating, differentiated cellular fraction, it can be conjectured that overexpression of ALDH1A1 is associated with a biological type of tumour which is more prone to chemotherapy. This hypothesis is supported by our findings, that increased expression of ALDH1A1 has been identified as a strong prognostic marker for improved clinical outcome in our subgroup analysis for patients having received adjuvant chemotherapy but not in the subgroup of patients having not received adjuvant treatment. Due to the low patient number in this subgroup of patients, however, this needs to be confirmed in further studies. In addition, our assumptions are in line with the clinical results of Chang et al., who reported a significant correlation between high expression of ALDH1 in ovarian cancer and response to chemotherapy . Bearing in mind that ALDH1 increases chemoresistance against cyclophosphamide, one can argue that this chemotherapeutic agent is not part of the standard chemotherapy regimen against pancreatic cancer. Moreover, increased chemoresistance against cyclophosphamide by ALDH1 does not exclude increased chemosensitivity to other chemotherapeutic agents. Regarding our in vitro data, we have shown that MiaPaca2 cells have a strong expression of ALDH1A1. Intriguingly, Monti et al. have demonstrated that MiaPaca2 cells exhibit the strongest response to chemotherapy when exposed to combined treatment with gemcitabine and 5-FU . These data would favour the hypothesis that increased expression of ALDH1A1 is not necessarily related to increased general chemoresistance but depends on the chemotherapeutical agent.
In summary, our study describes low expression of ALDH1A1 as an independent prognostic marker for a poor clinical outcome in pancreatic cancer on whole-mount tissue slides. These data are conflicting with a previous report, which has claimed increased expression of ALDH1A1 to be an adverse prognostic marker in a retrospective study. Therefore, to evaluate the role of ALDH1A1 as a prognostic and predictive marker for tumour progression and response to chemotherapy in pancreatic cancer, standarised prospective studies with a larger number of patients are required.
We thank Bettina Walter from the tissue bank of the National Centre for Tumour Disease (NCT) Heidelberg for technical help with tissue sections and immunohistology.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.View ArticlePubMedGoogle Scholar
- Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993, 165 (1): 68-72. 10.1016/S0002-9610(05)80406-4. discussion 72-63View ArticlePubMedGoogle Scholar
- Cameron JL, Riall TS, Coleman J, Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006, 244 (1): 10-15. 10.1097/01.sla.0000217673.04165.ea.View ArticlePubMedPubMed CentralGoogle Scholar
- Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH: Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg. 1996, 172 (5): 463-468. 10.1016/S0002-9610(96)00237-1. discussion 468-469View ArticlePubMedGoogle Scholar
- Hellan M, Sun CL, Artinyan A, Mojica-Manosa P, Bhatia S, Ellenhorn JD, Kim J: The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas. 2008, 37 (1): 19-24. 10.1097/MPA.0b013e31816074c9.View ArticlePubMedGoogle Scholar
- Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67 (3): 1030-1037. 10.1158/0008-5472.CAN-06-2030.View ArticlePubMedGoogle Scholar
- Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007, 1 (3): 313-323. 10.1016/j.stem.2007.06.002.View ArticlePubMedGoogle Scholar
- Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008, 98 (8): 1389-1397. 10.1038/sj.bjc.6604307.View ArticlePubMedPubMed CentralGoogle Scholar
- Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, Kanai Y, Kakizoe T: Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res. 1998, 89 (10): 1033-1040.View ArticlePubMedGoogle Scholar
- Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1 (5): 555-567. 10.1016/j.stem.2007.08.014.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009, 69 (8): 3382-3389. 10.1158/0008-5472.CAN-08-4418.View ArticlePubMedPubMed CentralGoogle Scholar
- Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009, 7 (3): 330-338. 10.1158/1541-7786.MCR-08-0393.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, et al: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009, 385 (3): 307-313. 10.1016/j.bbrc.2009.05.048.View ArticlePubMedGoogle Scholar
- Yoshida A, Rzhetsky A, Hsu LC, Chang C: Human aldehyde dehydrogenase gene family. Eur J Biochem. 1998, 251 (3): 549-557. 10.1046/j.1432-1327.1998.2510549.x.View ArticlePubMedGoogle Scholar
- Hilton J: Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res. 1984, 44 (11): 5156-5160.PubMedGoogle Scholar
- Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008, 59 (3): 340-349. 10.1016/j.lungcan.2007.08.033.View ArticlePubMedGoogle Scholar
- Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et al: Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 102 (5): 340-351.Google Scholar
- Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J: ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol. 2009, 22 (6): 817-823.PubMedPubMed CentralGoogle Scholar
- Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44 s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 103 (3): 382-390.Google Scholar
- Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S: Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009, 100 (6): 1062-1068. 10.1111/j.1349-7006.2009.01151.x.View ArticlePubMedGoogle Scholar
- Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009, 15 (12): 4234-4241. 10.1158/1078-0432.CCR-08-1479.View ArticlePubMedGoogle Scholar
- Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG, Matterne U, Mollberg N, Rahbari NN, Hinz U, et al: Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 2009, 101 (3): 457-464. 10.1038/sj.bjc.6605136.View ArticlePubMedPubMed CentralGoogle Scholar
- Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, et al: High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003, 98 (3): 474-483. 10.1002/cncr.11515.View ArticlePubMedGoogle Scholar
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 2001, 29 (9): e45-10.1093/nar/29.9.e45.View ArticlePubMedPubMed CentralGoogle Scholar
- Walsh N, O'Donovan N, Kennedy S, Henry M, Meleady P, Clynes M, Dowling P: Identification of pancreatic cancer invasion-related proteins by proteomic analysis. Proteome Sci. 2009, 7: 3-10.1186/1477-5956-7-3.View ArticlePubMedPubMed CentralGoogle Scholar
- Makinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M: Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. 1998, 18 (1B): 615-618.PubMedGoogle Scholar
- Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, Wiebke EA: Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg. 2003, 186 (5): 486-492. 10.1016/j.amjsurg.2003.07.002.View ArticlePubMedGoogle Scholar
- Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005, 92 (8): 1372-1381. 10.1038/sj.bjc.6602513.View ArticlePubMedPubMed CentralGoogle Scholar
- Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, Song E: Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS One. 5 (12): e15630-Google Scholar
- Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, Balzano G, Di Carlo V, Allavena P, Piemonti L: A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 2004, 445 (3): 236-247. 10.1007/s00428-004-1053-x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/275/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.